论文信息 - A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185.

A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185.

8010Background: KEYNOTE-185 (NCT02579863) evaluated Rd ± pembro in patients (pts) with newly diagnosed, ASCT-ineligible MM. Methods: Pts were randomized 1:1 to pembro (200 mg Q3W) + Rd (len 25 mg [...